Findings

What do systematic reviews say?

6 questions · 9 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 22.2%GRADE not reported 0 · 0%Very low 2 · 22.2%Low 5 · 55.6%Moderate 0 · 0%High 0 · 0%

Levamisole vs cyclophosphamide

Relapse · SSNS in children

It is very uncertain whether levamisole changes relapse: at end of therapy compared with cyclophosphamide (very low certainty).

4 findings from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 2.14 [0.22, 20.95]
2 studies · 97 participants
Very low
Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 1.17 [0.76, 1.81]
2 studies · 97 participants
Low
Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.89 [0.68, 1.16]
1 study · 40 participants
Low

Show 1 more finding

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.89 [0.73, 1.1]
1 study · 40 participants
Low

Levamisole vs cyclophosphamide

Frequent relapses · SSNS in children

The review found no eligible studies for this question.

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levamisole vs cyclophosphamide

Mean relapse rate/patient/month · SSNS in children

The review found no eligible studies for this question.

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Levamisole vs cyclophosphamide

Adverse effects: infection · SSNS in children

Levamisole showed no clear difference in adverse effects: infection compared with cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 1.08 [0.67, 1.75]
1 study · 40 participants
Low

Levamisole vs cyclophosphamide

Adverse effects: leucopenia · SSNS in children

Levamisole showed no clear difference in adverse effects: leucopenia compared with cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.25 [0.04, 1.48]
2 studies · 97 participants
Low

Levamisole vs cyclophosphamide

Adverse effects: abnormal liver function tests · SSNS in children

It is very uncertain whether levamisole changes adverse effects: abnormal liver function tests compared with cyclophosphamide (very low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.72]
1 study · 40 participants
Very low